OncoSec Medical Incorporated (ONCSQ)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
OncoSec Medical Incorporated (ONCSQ) with AI Score 52/100 (Hold). OncoSec Medical Incorporated is a late-stage immuno-oncology company focused on developing DNA-based therapeutics for cancer treatment. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026OncoSec Medical Incorporated (ONCSQ) Healthcare & Pipeline Overview
OncoSec Medical Incorporated, an immuno-oncology company, focused on intra-tumoral DNA-based therapeutics to stimulate anti-tumor immune responses. Despite clinical trial collaborations with Merck and Duke University, the company filed for Chapter 7 liquidation in 2023, impacting its pipeline of cancer treatments and COVID-19 therapies. The company's stock trades on the OTC market.
Investment Thesis
OncoSec Medical Incorporated's Chapter 7 liquidation filing in June 2023 represents a significant event for investors. The company's pipeline, which included multiple Phase 1 and Phase 2 clinical trials, is now subject to the bankruptcy proceedings. Key collaborations with Merck and Duke University are unlikely to continue. The company's market capitalization was $0.00B prior to liquidation. The high beta of 9.96 indicates extreme volatility, which is now largely irrelevant given the bankruptcy. Investors should be aware that recovery on OTC stocks after bankruptcy is highly uncertain.
Based on FMP financials and quantitative analysis
Key Highlights
- OncoSec Medical Incorporated filed for Chapter 7 liquidation on June 14, 2023.
- The company's market capitalization was $0.00B prior to liquidation.
- The company's pipeline included multiple Phase 1 and Phase 2 clinical trials targeting various cancers and COVID-19.
- OncoSec had clinical trial collaborations with Merck & Co., Inc. and research collaboration with Duke University.
- The stock trades on the OTC market, specifically the OTC Other tier.
Competitors & Peers
Strengths
- Proprietary DNA-based therapeutic technology.
- Clinical trial collaborations with established institutions.
- Diverse pipeline of immuno-oncology treatments.
Weaknesses
- Chapter 7 liquidation filing.
- Dependence on collaborations for funding.
- High risk of clinical trial failure.
Catalysts
- N/A: OncoSec Medical Incorporated filed for Chapter 7 liquidation on June 14, 2023.
Risks
- Ongoing: Chapter 7 bankruptcy proceedings.
- Ongoing: Loss of intellectual property.
- Ongoing: Inability to continue clinical trials.
- Potential: Legal claims from creditors.
- Potential: Delisting from the OTC market.
Growth Opportunities
- N/A: OncoSec Medical Incorporated filed for Chapter 7 liquidation on June 14, 2023. Therefore, there are no growth opportunities.
- N/A: OncoSec Medical Incorporated filed for Chapter 7 liquidation on June 14, 2023. Therefore, there are no growth opportunities.
- N/A: OncoSec Medical Incorporated filed for Chapter 7 liquidation on June 14, 2023. Therefore, there are no growth opportunities.
- N/A: OncoSec Medical Incorporated filed for Chapter 7 liquidation on June 14, 2023. Therefore, there are no growth opportunities.
- N/A: OncoSec Medical Incorporated filed for Chapter 7 liquidation on June 14, 2023. Therefore, there are no growth opportunities.
Opportunities
- N/A due to liquidation filing.
Threats
- Bankruptcy proceedings.
- Loss of intellectual property.
- Inability to continue clinical trials.
Competitive Advantages
- Proprietary intra-tumoral DNA-based therapeutic technology.
- Clinical trial collaborations with Merck & Co., Inc. and Duke University.
- Pipeline of Phase 1 and Phase 2 clinical trials.
About ONCSQ
OncoSec Medical Incorporated, formerly known as NetVentory Solutions Inc., was founded in 2008 and rebranded in March 2011 to focus on immuno-oncology. Headquartered in Pennington, New Jersey, the company specialized in designing, developing, and commercializing intra-tumoral DNA-based therapeutics aimed at stimulating and augmenting anti-tumor immune responses for cancer treatment. Their product pipeline included KEYNOTE-695, a Phase 2 trial for advanced melanoma, and TAVO + SARS-CoV-2 spike glycoprotein, a Phase 1 clinical trial for COVID-19. Additional trials included TAVO + epacadostat + pembrolizumab for squamous cell carcinoma of the head and neck, TAVO + nivolumab for breast cancer, and TAVO + CXCL9 for solid tumors, along with OMS-100 and OMS-102 for metastatic melanoma. OncoSec collaborated with Merck & Co., Inc. on KEYNOTE-695 and KEYNOTE-890 and with Duke University's Center for Applied Therapeutics to evaluate TAVO in combination with a HER2-plasmid vaccine. However, on June 14, 2023, OncoSec filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of New Jersey, ceasing its operations and development programs.
What They Do
- Developed intra-tumoral DNA-based therapeutics.
- Focused on stimulating anti-tumor immune responses.
- Conducted Phase 1 and Phase 2 clinical trials for cancer treatments.
- Developed a COVID-19 therapy in Phase 1 clinical trial.
- Collaborated with Merck & Co., Inc. on clinical trials.
- Partnered with Duke University for research.
Business Model
- Focused on developing and commercializing immuno-oncology therapeutics.
- Generated revenue through potential future sales of approved therapies.
- Relied on collaborations and partnerships for funding and clinical trials.
Industry Context
OncoSec Medical Incorporated operated within the competitive biotechnology industry, focusing on immuno-oncology. This sector involves developing therapies that harness the body's immune system to fight cancer. The industry is characterized by high research and development costs, lengthy clinical trial processes, and regulatory hurdles. Companies like OncoSec often collaborate with larger pharmaceutical firms to fund and conduct clinical trials. The failure rate for biotechnology companies is high, and OncoSec's bankruptcy reflects the challenges inherent in bringing novel therapies to market. Competitors focus on similar immuno-oncology approaches, creating a crowded and dynamic landscape.
Key Customers
- Patients with advanced melanoma.
- Patients with squamous cell carcinoma of the head and neck.
- Patients with breast cancer.
- Patients with solid tumors.
- Patients with COVID-19.
Financials
Chart & Info
OncoSec Medical Incorporated (ONCSQ) stock price: Price data unavailable
Latest News
No recent news available for ONCSQ.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ONCSQ.
Price Targets
Wall Street price target analysis for ONCSQ.
MoonshotScore
What does this score mean?
The MoonshotScore rates ONCSQ's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
ONCSQ OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, encompassing stocks that may not meet the minimum financial standards or have chosen not to provide current information to the market. These securities often include companies in bankruptcy, those with regulatory issues, or those that are thinly traded. Investing in OTC Other stocks carries significant risks due to the lack of regulatory oversight and limited financial disclosure compared to exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure.
- Low liquidity and wide bid-ask spreads.
- Potential for fraud or manipulation.
- Bankruptcy risk.
- Lack of regulatory oversight.
- Verify the company's bankruptcy status with the U.S. Bankruptcy Court.
- Attempt to locate any available financial statements.
- Assess the trading volume and bid-ask spread.
- Consult with a financial advisor.
- Understand the risks associated with OTC Other stocks.
- Determine the potential for recovery in bankruptcy proceedings.
- Research the company's assets and liabilities.
- Prior clinical trial collaborations with Merck & Co., Inc. and Duke University.
- Previous focus on developing immuno-oncology therapies.
- Listing on the OTC market, despite the bankruptcy.
Common Questions About ONCSQ
What does OncoSec Medical Incorporated do?
OncoSec Medical Incorporated was a late-stage immuno-oncology company focused on developing intra-tumoral DNA-based therapeutics to stimulate anti-tumor immune responses for cancer treatment. The company's pipeline included treatments for melanoma, squamous cell carcinoma, breast cancer, solid tumors, and COVID-19. OncoSec collaborated with Merck & Co., Inc. and Duke University to advance its clinical trials. However, the company filed for Chapter 7 liquidation in June 2023, ceasing its operations and development programs.
What do analysts say about ONCSQ stock?
Given OncoSec Medical Incorporated's Chapter 7 liquidation filing in June 2023, there is no current analyst coverage or consensus. The company's stock trades on the OTC market, and its financial viability is highly uncertain. Investors should be aware that the company is undergoing bankruptcy proceedings, and any prior valuations or growth considerations are no longer applicable. Trading in this stock carries substantial risk.
What are the main risks for ONCSQ?
The primary risk for ONCSQ is the Chapter 7 bankruptcy filing, which indicates that the company is undergoing liquidation. This means that the company's assets will be sold to pay off creditors, and there is a high likelihood that shareholders will receive little to no recovery. Additional risks include the loss of intellectual property, the inability to continue clinical trials, and potential legal claims from creditors. The stock's OTC listing further increases the risk due to limited regulatory oversight and low liquidity.
What are the key factors to evaluate for ONCSQ?
OncoSec Medical Incorporated (ONCSQ) currently holds an AI score of 52/100, indicating moderate score. Key strength: Proprietary DNA-based therapeutic technology.. Primary risk to monitor: Ongoing: Chapter 7 bankruptcy proceedings.. This is not financial advice.
How frequently does ONCSQ data refresh on this page?
ONCSQ prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven ONCSQ's recent stock price performance?
Recent price movement in OncoSec Medical Incorporated (ONCSQ) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary DNA-based therapeutic technology.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider ONCSQ overvalued or undervalued right now?
Determining whether OncoSec Medical Incorporated (ONCSQ) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying ONCSQ?
Before investing in OncoSec Medical Incorporated (ONCSQ), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change due to the ongoing bankruptcy proceedings.